Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: Texarkana, TX-Texarkana, AR MSA — September 2026
Texarkana's thin life sciences bench meets Houston's hiring pull.
Texarkana unemployment rose to 4.70% from 4.40% a year ago even as Houston's $8.8B in new biomanufacturing investment threatens to draw scarce regional quality and regulatory talent away from smaller markets.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Texarkana unemployment rate: 4.70% — vs 4.40% one year earlier
- Texas pharma establishment growth: 56.2% — since 2019, outpacing local talent pipeline
- Houston biomanufacturing investment: $8.8B combined — Eli Lilly + Bristol Myers Squibb, Generation Park
- Texarkana Health Care/Social Assistance avg wage: $61,619 — 25.1% of tracked metro sector employment
Key takeaways
Texarkana's labor slack is deepening, but talent isn't deep to begin with.
Unemployment moved from 4.40% to 4.70% year-over-year, yet the metro's life sciences-relevant workforce is concentrated in a small health care base rather than a broad biotech bench. A looser headline labor market does not translate into looser specialized-talent supply here.
Houston's manufacturing buildout is a regional retention risk, not just a Houston story.
Eli Lilly and Bristol Myers Squibb's combined $8.8B in Generation Park investment creates over 600 new jobs competing statewide for quality and operations talent. Texarkana employers should treat these announcements as a recruiting threat to existing staff, not a distant market development.
Regulatory affairs scarcity reaches even thin regional markets.
National VP Regulatory Affairs compensation of $320K-$580K reflects an acute, structural shortage rather than a cyclical blip tied to GLP-1 and faster FDA pathway demands. Smaller metros without deep regulatory benches may need to benchmark against national, not local, compensation data to retain scarce expertise.
Pipeline investment is underway, but it won't close the gap fast.
San Jacinto College's NIBRT-licensed biotech training center, the only one in the southern U.S., signals state-level recognition of the technician shortage. Texarkana-area employers likely won't see meaningful graduate flow for several hiring cycles, making near-term retention strategy more urgent than pipeline-dependent workforce planning.
Median advertised pay by role — Texarkana, TX-Texarkana, AR MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $84,986 | $125,310 | $136,499 | Significant increase | $131,354 |
| Clinical Research Associate * | $58,220 | $81,374 | $98,325 | Significant increase | $90,956 |
| Lab Technician * | $37,740 | $45,314 | $49,226 | Stable | $47,402 |
| Regulatory Affairs Specialist * | $70,793 | $95,949 | $116,373 | Moderate decline | $104,000 |
| Clinical Data Manager * | $96,493 | $122,953 | $136,780 | Stable | $123,031 |
| Biostatistician * | $104,135 | $141,493 | $163,775 | Significant increase | $133,322 |
| Validation Engineer * | $82,458 | $105,350 | $113,458 | Significant increase | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Texarkana's unemployment rate climbed to 4.70% in the most recent reading, up from 4.40% a year earlier, even as the metro's small Health Care and Social Assistance base — 7,546 workers at an average $61,619 wage — continues to anchor local life sciences-adjacent employment. Statewide biomanufacturing expansion (Eli Lilly's $6.5B Houston project, Bristol Myers Squibb's $2.3B facility) is pulling skilled operators and quality talent toward major metros, leaving smaller markets like Texarkana more exposed to outmigration of credentialed talent than to direct competition for new facility jobs.
What it means
Rising metro unemployment alongside a thin, concentrated local talent base means Texarkana-area life sciences employers compete less on volume and more on being the only credible regional option for specialized clinical, quality, and regulatory talent — losing even a handful of staff to Houston or Dallas-area manufacturing buildouts can materially strain headcount plans. With Texas pharma establishment growth running at 56.2% since 2019 against a still-undersupplied technician and regulatory pipeline, build-vs-outsource decisions for clinical and quality functions may increasingly favor CRO partnerships over local hires who are difficult to replace quickly. Consider reviewing retention compensation for regulatory and quality roles against statewide rather than purely metro-level pay data, given how readily qualified staff can be drawn toward Houston-area biomanufacturing expansion.
Looking ahead
Worth watching: Texarkana unemployment has risen three consecutive readings (4.40% to 4.50% to 4.70%); watch whether this reflects genuine demand softening or seasonal noise before adjusting hiring plans.
Emerging pressure point: Continued hiring momentum at Houston-area biomanufacturing sites may accelerate departures among Texarkana's limited pool of quality and regulatory staff. Track exit interview data for destination employers over the next two quarters.
Early indicator: Texas pharma establishment growth (56.2% since 2019) against an undersupplied technician pipeline suggests statewide wage pressure on credentialed roles will likely outpace Texarkana-specific wage data. Watch Dallas Fed manufacturing wage readings as a leading signal for regional pay resets.
Potential inflection point: National September layoff announcements (BioMarin, Bristol Myers) are concentrated in consolidation functions, not execution roles; monitor whether any released regulatory or quality talent enters smaller Texas markets as remote-capable hires.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.